ATE384720T1 - Chinucledin - derivate und deren verwendung - Google Patents

Chinucledin - derivate und deren verwendung

Info

Publication number
ATE384720T1
ATE384720T1 AT03787742T AT03787742T ATE384720T1 AT E384720 T1 ATE384720 T1 AT E384720T1 AT 03787742 T AT03787742 T AT 03787742T AT 03787742 T AT03787742 T AT 03787742T AT E384720 T1 ATE384720 T1 AT E384720T1
Authority
AT
Austria
Prior art keywords
diseases
disorders
nervous system
derivatives
disorders related
Prior art date
Application number
AT03787742T
Other languages
German (de)
English (en)
Inventor
Dan Peters
Gunnar M Olsen
Elsebet Ostergaard Nielsen
Philip K Ahring
Tino Dyhring Jorgensen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE384720T1 publication Critical patent/ATE384720T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03787742T 2002-08-14 2003-08-13 Chinucledin - derivate und deren verwendung ATE384720T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201208 2002-08-14
DKPA200201472 2002-10-02

Publications (1)

Publication Number Publication Date
ATE384720T1 true ATE384720T1 (de) 2008-02-15

Family

ID=31889349

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03787742T ATE384720T1 (de) 2002-08-14 2003-08-13 Chinucledin - derivate und deren verwendung

Country Status (18)

Country Link
US (2) US20050245567A1 (enExample)
EP (2) EP1532144B1 (enExample)
JP (1) JP2005538187A (enExample)
KR (1) KR20050055711A (enExample)
CN (1) CN100513406C (enExample)
AT (1) ATE384720T1 (enExample)
AU (1) AU2003250322B2 (enExample)
BR (1) BR0313153A (enExample)
CA (1) CA2493245A1 (enExample)
DE (1) DE60318860T2 (enExample)
IL (1) IL166254A0 (enExample)
IS (1) IS7742A (enExample)
MX (1) MXPA05001702A (enExample)
NO (1) NO20051264L (enExample)
NZ (1) NZ538058A (enExample)
PL (1) PL375533A1 (enExample)
RU (1) RU2323217C2 (enExample)
WO (1) WO2004016608A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
WO2005016923A1 (en) * 2003-08-13 2005-02-24 Neurosearch A/S Novel quinuclidine derivatives and their pharmaceutical use
US7309699B2 (en) 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
US20050137398A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
US7160876B2 (en) 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137203A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
US7241773B2 (en) 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
US20050245531A1 (en) * 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP2008523058A (ja) * 2004-12-10 2008-07-03 アボット・ラボラトリーズ 縮合ビシクロ複素環置換キヌクリジン誘導体
RU2418797C2 (ru) * 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
KR20080048550A (ko) * 2005-09-23 2008-06-02 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
FR2904002A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de la lanosterol synthetase dans le traitement de l'acne ou de l'hyperseborrhee
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102573842A (zh) * 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
BR122014023207A2 (pt) 2010-09-23 2019-05-28 Abbvie Inc. Compostos derivados de aza-adamantano, seus usos e processos para a preparação destes compostos
US20120220729A1 (en) * 2011-02-28 2012-08-30 Boehringer Ingelheim International Gmbh Liquid phase separation of plasmid dna isoforms and topoisomers
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
CN105263492B (zh) * 2013-01-15 2018-04-10 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用
JP2016508159A (ja) * 2013-01-15 2016-03-17 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
AU2016274694A1 (en) 2015-06-10 2018-01-18 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3534053A (en) * 1967-05-24 1970-10-13 American Home Prod Quinuclidine derivatives
SU495310A1 (ru) * 1974-03-05 1975-12-15 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Хинуклидил-3-диарал(гетерил) карбинолы, про вл ющие антигистаминную, антисеротониновую и антиаллергическую активность и способ их получени
DE3718317A1 (de) * 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
CA1307790C (en) * 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
US5405853A (en) * 1987-09-10 1995-04-11 Merck Sharpe & Dohme Ltd. Thiadiazoles useful in the treatment of senile dementia
JP2752143B2 (ja) * 1988-04-01 1998-05-18 三共株式会社 カルバペネム誘導体
EP0363085A3 (en) * 1988-10-03 1991-03-27 Beecham Group Plc Novel compounds
IT1227729B (it) * 1988-12-23 1991-05-06 Savio Spa Procedimento e dispositivo per la rimozione delle fibre deteriorate durante il riattacco del filo in un filatoio open-end
YU84791A (sh) * 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklicni 1-aza-cikloalkalni
AU8405991A (en) * 1990-08-31 1992-03-30 Nippon Shinyaku Co. Ltd. Pyrimidine derivative and medicine
ZA92278B (en) * 1991-02-01 1992-10-28 Akzo Nv 3-quinuclidine derivatives
GB9201749D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Plc Medicaments
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
JPH09512804A (ja) * 1994-05-06 1997-12-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ１ｄアンタゴニストとして有用なビフェニルカルボキシアミド類
JPH0840999A (ja) * 1994-08-04 1996-02-13 Yamanouchi Pharmaceut Co Ltd フルオロインダン誘導体
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
JPH08134067A (ja) * 1994-11-11 1996-05-28 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
US5512574A (en) * 1994-12-21 1996-04-30 American Home Products Corporation Quinuclidine and azabicyclo 2.2.1! heptane pyrazinyl ethers as muscarinic agonists
AU7674796A (en) * 1995-11-13 1997-06-05 Eli Lilly And Company Method for treating anxiety
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
FR2754261B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de quinuclidine, leur preparation et leur application en therapeutique
AU7871498A (en) * 1996-12-20 1998-07-17 Novo Nordisk A/S A method of treating hypercholesterolemia and related disorders
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
WO1999042461A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
JP4616971B2 (ja) * 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
ATE385497T1 (de) * 2000-12-01 2008-02-15 Neurosearch As 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten

Also Published As

Publication number Publication date
US20050245567A1 (en) 2005-11-03
RU2323217C2 (ru) 2008-04-27
MXPA05001702A (es) 2005-04-19
NZ538058A (en) 2006-11-30
EP1532144B1 (en) 2008-01-23
CN1675205A (zh) 2005-09-28
EP1905771A3 (en) 2008-11-26
EP1905771A2 (en) 2008-04-02
AU2003250322B2 (en) 2010-01-21
US20090005390A1 (en) 2009-01-01
AU2003250322A1 (en) 2004-03-03
DE60318860D1 (de) 2008-03-13
RU2005101748A (ru) 2006-01-20
EP1532144A1 (en) 2005-05-25
IS7742A (is) 2005-03-14
PL375533A1 (en) 2005-11-28
JP2005538187A (ja) 2005-12-15
BR0313153A (pt) 2005-06-28
CA2493245A1 (en) 2004-02-26
WO2004016608A1 (en) 2004-02-26
IL166254A0 (en) 2006-01-15
HK1080860A1 (zh) 2006-05-04
NO20051264L (no) 2005-05-18
KR20050055711A (ko) 2005-06-13
CN100513406C (zh) 2009-07-15
DE60318860T2 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
DE60318860D1 (de) Chinucledin - derivate und deren verwendung
DE60326894D1 (de) 1,4-Diazabicycloalkanderivate, deren Herstellung und Verwendung
ATE385497T1 (de) 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten
ATE477253T1 (de) Neuartige oxadiazol-derivate und deren medizinische verwendung
DE60108639D1 (de) Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
DE60310548D1 (de) Diazabicyclische biarylderivate
ATE345342T1 (de) 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zur ihre herstellung und therapeutical verwendung
ATE289310T1 (de) Heteroaryl-diazabicycloalkanderivaten als cns- modulatoren
DK1713487T3 (da) Diazabicykliske aryl-derivater som kolinerge receptor-modulatorer
ATE341548T1 (de) Neue verbindungen, deren herstellung und verwendung
ATE437880T1 (de) Dimere azacyclische verbindungen und deren verwendung
MXPA05006861A (es) Derivados arildiazabiciclicos novedosos.
DE60307102D1 (de) 3-substituierte chinuklidine und deren verwendung
ATE473978T1 (de) Neue diazabicyclische arylderivate und medizinische verwendung dafür
ATE401334T1 (de) Neue azacyclische ethinylderivate
DE602004031124D1 (de) Neue chinuklidinderivative und deren pharmazeutische verwendung
ATE460416T1 (de) Neuartige 1,4-diazabicycloä3.2.2ünonan-derivate und deren medizinische verwendung
DE60202667D1 (de) Diazabicyclo [2.2.1] heptanderivate
MX2007004245A (es) Nuevos derivados de arilo azabiciclicos y su uso medico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties